Tandem Diabetes Care (TNDM) Expected to Announce Earnings on Wednesday

Tandem Diabetes Care (NASDAQ:TNDM) will likely be issuing its Q1 2025 quarterly earnings data after the market closes on Wednesday, April 30th. Analysts expect Tandem Diabetes Care to post earnings of ($0.60) per share and revenue of $220.19 million for the quarter.

Tandem Diabetes Care Price Performance

Shares of TNDM opened at $16.35 on Wednesday. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care has a fifty-two week low of $15.75 and a fifty-two week high of $53.69. The company has a market cap of $1.09 billion, a P/E ratio of -8.47 and a beta of 1.52. The firm’s 50 day moving average price is $21.11 and its 200 day moving average price is $29.69.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on TNDM shares. Morgan Stanley lowered Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $45.00 to $22.00 in a report on Wednesday, March 5th. Barclays lowered their price objective on Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Royal Bank of Canada reduced their target price on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating on the stock in a report on Thursday, February 27th. The Goldman Sachs Group lowered their price target on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Finally, Citigroup lowered shares of Tandem Diabetes Care from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $35.00 to $24.00 in a report on Tuesday, March 4th. Eight research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.88.

Insider Activity at Tandem Diabetes Care

In other news, COO Jean-Claude Kyrillos acquired 10,538 shares of Tandem Diabetes Care stock in a transaction on Friday, March 7th. The stock was bought at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the purchase, the chief operating officer now owns 10,538 shares in the company, valued at $190,948.56. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 2.20% of the company’s stock.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.